In this context, Gollob et al have recently performed a phase I trial of 5-AZA-CdR plus high-dose IL2 in CM and renal carcinoma patients, demonstrating that the combination is well-tolerated and that 5-AZA-CdR may enhance the activity of IL2 [109]. This evidence concerns the gene IL2 and renal carcinoma.